I started my #mindcandy in February 2023, just when Swedish researchers grew self-assembling electrodes inside living brain tissue, a string of isolated-seeming lab curiosities began to add up to something bigger. Organoid intelligence research. 800,000 neurons learning to play Pong. Necrobots built from dead spiders. Each one looked like a curiosity on its own. Together, they quietly signaled something else: biology was becoming a computing platform.
By 2024, those threads started combining into real engineering. Networked organoid computers. Lab-grown brain tissue driving robots. DARPA- and SoftBank-funded biohybrid robots that blurred the line between living and dead cells.
In 2025, the pattern finally got names — Synthetic Biological Intelligence, the synthetic economy. Neurons merged with silicon processors. DNA-hacking became a live security concern. A wave of cyborg experiments and “necrosis as a design variable” projects made the shift explicit: biology is programmable, death is a design variable, and identity is a mashup.
By April 2026, the loop closed. Electrodes were growing directly inside living mouse brains. Dead bacteria were being reanimated with transplanted genomes. This was the exact signal from that February 2023 opening moment — thirty-eight months more advanced, and now fully operational inside living organisms.
What this means for your business
You might be reading this and thinking: interesting, but what does it have to do with my company? We’re not in the brain organoid business. We don’t build biohybrid robots. We’re not engineering life. Not yet.
Here’s what’s worth considering as the biological-digital boundary dissolves:
Manufacturing. When you can grow materials instead of fabricating them — biocement, mycelium-based textiles, bio-plastics — the entire supply chain shifts. The factory becomes a lab. The lab becomes a farm. The farm becomes a computing platform. Companies that depend on traditional manufacturing are sitting on the wrong side of a category shift.
Computing. Biological systems can already compute. That doesn’t mean your data center is obsolete tomorrow — it means the next generation of computing architecture will be hybrid: part silicon, part biological, part quantum. The company that understands only one of those three is the one that gets disrupted by the company using all three.
Healthcare. When cells are programmable, when organs can be 3D-printed, when gene editing is being abstracted toward natural language, the current model of diagnose-and-treat gives way to programme-and-prevent. Pharma, medical devices, and insurance are all built on assumptions about what bodies can and cannot do. Those assumptions are dissolving along with the boundary.
Agriculture. Smart soil. Precision fermentation. Bio-factories made from insects. Genetically modified crops designed by AI. Seaweed farming at scale. The food system is being re-engineered from the cellular level up.
Security. If DNA is hackable, if biological systems are programmable, then cybersecurity expands into biosecurity. Wetware hacking. Molecular-level threats. Attack surfaces that are literally alive. The frameworks built for digital systems don’t cover biological ones. Yet.
Identity. Brain-computer interfaces that extend your cognition into machines. Digital twins that clone your behavior. Thanabots that simulate conversations with the dead. AI that mediates your consciousness. “Who am I?” is becoming an engineering question as much as a philosophical one.
How to prepare for science fact
This isn’t about predicting which specific biological technology will disrupt your industry. It’s about recognizing that the category boundary your business plan depends on — biological vs. digital, living vs. engineered, natural vs. artificial — isn’t stable.
Look at the core assumptions underlying your business model. Which ones depend on that boundary staying in place? Which ones assume computing means silicon, manufacturing means fabrication, intelligence means human brains, death means the end of economic utility?
Now ask: what happens to those assumptions in a world where biology is programmable, death is a design variable, and identity is a mashup?
If you don’t have an answer, that’s fine. Nobody does. But the company asking the question has a head start over the one that isn’t — and in a world where brain organoids go from petri dish to networked computer in thirty-six months, that head start matters.
